This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for rheumatoid arthritis and patient flow dynamics through lines of therapy are also included. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral disease-modifying antirheumatic drugs (DMARDs).
Buy your copy of this report @ http://www.reportsnreports.com/reports/174279-united-states-market-for-rheumatoid-arthritis-pharmacotherapeutics.html
Report Details:
Published: July 2012
No. of Pages: 110
Price: US$6000
Major points covered in Table of Contents of this report include:
Executive Summary
Market Overview
Total Rheumatoid Arthritis Pharmacotherapeutics Market
- External Challenges: Drivers and Restraints
- Forecasts and Trends
- Demand Analysis
- Market Share and Competitive Analysis
TNF Inhibitor Segment Breakdown
Non-TNF Biologics Segment Breakdown
Novel Oral DMARDs Segment Breakdown
The Last Word (Conclusions and Implications)
Appendix
